Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab continuation versus discontinuation with second-line chemotherapy after progression in HER2-positive metastatic breast cancer
2006-000703-42Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoints: Progression-free survival and Overall survival. Started Jul 2007; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-000703-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000703-42.